How Do Your Salespeople Become "Triple Threat" Sellers? [VIDEO]
What skills approach do B2B salespeople need to win more deals? Learn by checking out this video from Corporate Visions. Call 1-800-360-SELL for more!
Top 5 Shameful Office Sins to Stay Clear of
There's always one person in the office who never offers to make the teas or coffees, yet are the first to put their order in. Or that person who is always
SENSCIS Research Study
We all have reasons to keep fighting Scleroderma Lung Disease. If you have been diagnosed with Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD), you could be eligible to participate in SENSCISTM, a clinical research study of an investigational drug for SSc-ILD called nintedanib. Nintedanib is an oral drug that has been approved in the United States and Europe for the treatment of idiopathic pulmonary fibrosis, which is a disease similar to SSc-ILD. Nintedanib has not been approved for the treatment of SSc-ILD. To pre-qualify for this study, you must: Be 18 years of age or older Be diagnosed with SSc-ILD Have impaired lung function as demonstrated by Pulmonary Lung Function Test
e&e IT Consulting Services Inc.: It's Hershey Restaurant Week! What is your favorite...
Vote on this poll.
Team McLean Communications
Thank you for choosing to support McLean Communications for On Tap for CASA on Saturday, March 4, 2017. This promises to be a day of fun and camaraderie to support a good cause. Your gift today helps support New Hampshire’s abused and neglected children by providing them with a caring, professionally-trained advocate to make sure the child’s best interests are preserved during the court process that determines their future About Team McLean Communications McLean Communications produces a number of titles including New Hampshire Magazine, Parenting New Hampshire, New Hampshire Home, the New Hampshire Business Review and a number of other specialty publications. As the names of our publications suggest, McLean is deeply connected with the NH…